Axikin Pharmaceuticals receives No Objection Letter for Phase 2 study of AXP1275 in Canada.
July 10th, 2013 — On the heels of a successful Phase 1 study for AXP1275, Axikin Pharmaceuticals submitted a Clinical Trial Application for AXP1275 on June 10, 2013, for which a No Objection Letter was received. The Phase 2 study will be a 3-centered study to investigate the efficacy of AXP1275 in ameliorating the airways hyperreactivty and inflammatory response in allergen-challenged allergic individuals.
AXP1275 represents a novel class of orally-available allosteric modulators against the CCR3 chemokine receptor. Phase I safety and tolerability data did not reveal any liabilities of the compound and has demonstrated the potential for once-daily oral dosing.
The Phase IIa study is a multi-center, randomized, placebo-controlled, double-blind cross-over study in allergen-challenged subjects, designed to measure end-points for both airways hyperreactivity and inflammation. More information on the study can be found here.
About Axikin Pharmaceuticals Inc.:
Axikin Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused exclusively on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Axikin was spun out from Actimis Pharmaceuticals, in June 2008. Investors include Sanderling Ventures and Mitsui & Co. Venture Partners.
Axikin Pharmaceuticals Inc.
Kevin Bacon, Ph.D.
6185 Cornerstone Ct., Suite 106
San Diego, CA 92121
Phone:+1 (858) 458 - 1890
Fax: +1 (858) 642 - 6962